

BRITISH SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS

England & Wales · Charity number 1123760

Details

Other names	BRITISH SOCIETY FOR HISCOMPATIBILITY AND IMMUNGENETICS
Status	Registered
Legal form	Charitable company
Company number	06078396
Registered	2008-04-18
Register	View on the Charity Commission register

Contact

Address	Fountain Precinct 4th Floor Orchard Lane Wing Balm Green Sheffield S1 2JA
---------	---

Phone	01625 664514
-------	--------------

Email	accounts@bshi.org.uk
-------	--

Website	www.bshi.org.uk
---------	--

Activities

Objects: TO PROMOTE AND PROTECT HEALTH FOR THE PUBLIC BENEFIT IN PARTICULAR BY:A) DEVELOPING AND MAINTAINING GOOD PRACTICE IN HISTOCOMPATIBILITY AND IMMUNOGENETICS BY ENSURING THE HIGHEST PROFESSIONAL STANDARDS OF COMPETENCE;B) ENCOURAGING THE ADVANCEMENT OF SCIENTIFIC RESEARCH AND KNOWLEDGE AND OF ITS APPLICATION IN ALL ASPECTS OF HISTOCOMPATIBILITY AND IMMUNOGENETICS AND DISSEMINATING THE USEFUL RESULTS THEREOF

Activities: The Annual Conference provides an educational programme of lectures.Training courses are held to support trainee scientists undertake higher qualifications.A CPD scheme helps members to maintain the knowledge and skills required to practice.A bursary scheme helps members to attend scientific and educational meetings.

Classification

- **How:** Makes Grants To Individuals, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups, The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED IN PRACTICE NATIONAL
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£103,753	£81,541	-	-
2023-12-31	£81,529	£72,615	-	-
2022-12-31	£87,581	£76,045	-	-
2021-12-31	£47,064	£74,152	-	-
2020-12-31	£35,927	£71,643	-	-

Trustees

Name	Role	Appointed
Aurona Gerber		2025-12-01
Corinna Freeman		2022-12-07
Dr Julie Johnson		2024-12-13
Dr Olivia Shaw		2022-12-07
Dr Raymond Fernando		2023-12-02
Dr Sharon Vivers		2024-12-01
Helena Lee		2026-04-17
RICHARD BATTLE		2012-05-31
Rebecca McGuire		2024-02-01
Sarah Grace Blow		2025-10-01
Sarah Maxfield		2023-11-01

Accounts

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2024

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2024

Report of the Trustees	1 to 4
Independent Examiner's Report to the Trustees	5
Statement of Financial Activities	6
Statement of Financial Position	7
Notes to the Financial Statements	8 to 13
Detailed Statement of Financial Activities	14 to 15

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2024

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference was held in person in 2024. The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present short talks and case studies.

Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

BSHI supplies and administers a Diploma in Histocompatibility and Immunogenetics, to facilitate specialist learning in the field. Graduating diplomats received their awards at the Annual Conference.

A successful series of one and two day training courses were held to support BSHI Diploma, Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

Special Interest Groups

The special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG with meetings held this year around platelets and transplanting highly sensitised patients.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Microsoft Teams, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have again increased to £121,509 which leaves the charity in a strong position to continue to pursue its objectives for the foreseeable future.

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Richard Battle
Daniel Eggleston
Corinna Freeman
Helena Lee
Jessie Martin
Sarah Peacock
Emily Ryan
Olivia Shaw
Carla Rosser
(Appointed: 23 August 2024)
Rachel Smith
(Resigned: 31 January 2024)
Sarah Maxfield
(Appointed: 23 August 2024)
Rebecca McGuire
(Appointed: 02 February 2024)
Raymond Fernando
(Appointed: 02 February 2024)

Secretary Carla Rosser

Independent examiner Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2024

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

10 September 2025

Corinna Freeman.....

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2024

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

10 September 2025

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2024

	Notes	Unrestricted funds £	2023 £
Income and endowments from:			
Charitable activities	3	102,368	80,889
Other trading activities	4	-	(426)
Investments	5	1,385	1,066
Total		103,753	81,529
Expenditure on:			
Charitable activities	6/7	(81,541)	(72,615)
Total		(81,541)	(72,615)
Net income		22,212	8,914
Reconciliation of funds			
Total funds brought forward		99,297	90,383
Total funds carried forward		121,509	99,297

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2024

	Notes	2024 £	2023 £
Fixed assets			
Tangible assets	14	-	29
		<u>-</u>	<u>29</u>
Current assets			
Debtors	15	29,305	19,380
Cash at bank and in hand		105,047	88,658
		<u>134,352</u>	<u>108,038</u>
Creditors: amounts falling due within one year	16	(12,843)	(8,770)
Net current assets		<u>121,509</u>	<u>99,268</u>
Total assets less current liabilities		<u>121,509</u>	<u>99,297</u>
Net assets		<u>121,509</u>	<u>99,297</u>
The funds of the charity			
Unrestricted income funds	17	121,509	99,297
Total funds		<u>121,509</u>	<u>99,297</u>

For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:

.....
Corinna Freeman
Trustee

10 September 2025

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2024

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

During 2024 BSHI was able to continue with its objectives with another successful year of member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income, and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

3. Income from charitable activities

	2024	2023
	£	£
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	18,500	17,850
Subscriptions	27,030	26,080
Conference	3,243	2,800
Qualifications	43,735	24,045
	92,508	70,775
<i>Other member activities</i>		
Other member activities	225	-
Income from charitable activities	9,635	10,114
	9,860	10,114
	102,368	80,889

4. Income earned from other activities

	2024	2023
	£	£
Fund raising events	-	(426)
	-	(426)

5. Investment income

	2024	2023
	£	£
Unrestricted funds		
Bank interest receivable	1,385	1,066
	1,385	1,066

6. Costs of charitable activities by fund type

	2024	2023
	£	£
Unrestricted funds		
Charitable activities	34,044	25,627
Support costs	47,497	46,988
	81,541	72,615

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

7. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2024	2023
	£	£	£	£
Support costs				
Charitable activities	34,044	47,497	81,541	72,615

8. Analysis of support costs

	2024	2023
	£	£
Charitable activities		
Management	444	-
Finance	1,359	1,288
Computer costs	188	560
Depreciation & amortisation	29	10
EBS Admin charges	32,628	31,697
International Journal of Immunogenetics	6,500	6,500
Print, post & stationery	28	53
Subscriptions	-	580
Telephone	309	67
Governance costs	6,012	6,233
	47,497	46,988

9. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2024	2023
	£	£
Depreciation of owned fixed assets	-	10
Accountancy fees	1,440	1,440
(Gain)/Loss on disposal of intangible fixed assets	29	-

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

10. Particulars of employees

	2024	2023
Employees	0	0
	<u>0</u>	<u>0</u>

12. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

13. Intangible fixed assets

	Intangible asset 1
	£
Cost or valuation	
At 01 January 2024	6,668
At 31 December 2024	<u>6,668</u>
Amortisation	
At 01 January 2024	6,668
At 31 December 2024	<u>6,668</u>
Net book values	
At 31 December 2024	<u>-</u>
At 31 December 2023	<u>-</u>

14. Tangible fixed assets

	Plant and machinery
	£
Cost or valuation	
At 01 January 2024	380
Disposals	(380)
At 31 December 2024	<u>-</u>
Depreciation	
At 01 January 2024	351
Disposals	(351)
At 31 December 2024	<u>-</u>
Net book values	
At 31 December 2024	<u>-</u>
At 31 December 2023	<u>29</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

15. Debtors

	2024 £	2023 £
Amounts due within one year:		
Trade debtors	29,284	19,380
Prepayments and accrued income	21	-
	29,305	19,380

16. Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	11,403	7,330
Accruals and deferred income	1,440	1,440
	12,843	8,770

17. Movement in funds

Unrestricted Funds

	Balance at 01/01/2024 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2024 £
<i>General</i>				
General	99,297	103,753	(81,541)	121,509
	99,297	103,753	(81,541)	121,509

Unrestricted Funds - Previous year

	Balance at 01/01/2023 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2023 £
<i>General</i>				
General	90,383	81,529	(72,615)	99,297
	90,383	81,529	(72,615)	99,297

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2024

18. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	-	121,509	121,509
	-	-	121,509	121,509

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	29	99,268	99,297
	-	29	99,268	99,297

19. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2024

	2024 £	2023 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising (Charitable activities)	18,500	17,850
Subscriptions (Charitable activities)	27,030	26,080
Conference (Charitable activities)	3,243	2,800
Qualifications (Charitable activities)	43,735	24,045
Other member activities (Other member activities)	225	-
Income from charitable activities (Other member activities)	9,635	10,114
	102,368	80,889
Other trading activities		
Fund raising events	-	(426)
	-	(426)
Investments		
Bank interest receivable	1,385	1,066
	1,385	1,066
Total incoming resources	103,753	81,529
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity (Charitable activities)	(34,044)	(25,627)
	(34,044)	(25,627)
SUPPORT COSTS		
Management		
Management (Charitable activities)	(444)	-
	(444)	-
Finance		
Finance (Charitable activities)	(1,359)	(1,288)
	(1,359)	(1,288)
Computer costs		
Computer costs (Charitable activities)	(188)	(560)
	(188)	(560)
Depreciation & amortisation		
Depreciation & amortisation (Charitable activities)	(29)	(10)
	(29)	(10)
EBS Admin charges		
EBS Admin charges (Charitable activities)	(32,628)	(31,697)
	(32,628)	(31,697)
International Journal of Immunogenetics		
International Journal of Immunogenetics (Charitable activities)	(6,500)	(6,500)

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2024

	(6,500)	(6,500)
Print, post & stationery		
Print, post & stationery (Charitable activities)	(28)	(53)
	<u>(28)</u>	<u>(53)</u>
Subscriptions		
Subscriptions (Charitable activities)	-	(580)
	<u>-</u>	<u>(580)</u>
Telephone		
Telephone (Charitable activities)	(309)	(67)
	<u>(309)</u>	<u>(67)</u>
Governance costs		
Governance costs (Charitable activities)	(6,012)	(6,233)
	<u>(6,012)</u>	<u>(6,233)</u>
Total resources expended	<u>(81,541)</u>	<u>(72,615)</u>
Net Income	<u><u>22,212</u></u>	<u><u>8,914</u></u>

Accounts

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements

For the year ended 31 December 2023

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2023

Report of the Trustees	1 to 4
Independent Examiner's Report to the Trustees	5
Statement of Financial Activities	6
Statement of Financial Position	7
Notes to the Financial Statements	8 to 13
Detailed Statement of Financial Activities	14 to 15

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2023

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2023. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference was held in person in 2023. The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present short talks and case studies.

Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2023

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduating diplomats received their awards at the Annual Conference.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

Special Interest Groups

The three special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Cisco Webex and Zoom Meeting to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have again increased to £99,297 which leaves the charity in a strong position to continue to pursue its objectives for the foreseeable future.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2023

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Richard Battle
Daniel Eggleston
(Appointed: 15 February 2023)
Corinna Freeman
(Appointed: 15 February 2023)
Helena Lee
Jessie Martin
Sarah Peacock
Emily Ryan
Olivia Shaw
(Appointed: 15 February 2023)
Mian Chen
(Resigned: 15 February 2023)
Carla Rosser
Deborah Sage
(Resigned: 01 September 2023)
Franco Tavarozzi
(Resigned: 01 September 2023)
Rachel Smith

Secretary

Carla Rosser

Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2023

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by



.....
Corinna Freeman

22 August 2024

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2023

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.



Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

22 August 2024

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2023

	Notes	Unrestricted funds £	2022 £
Income and endowments from:			
Charitable activities	2	80,889	86,895
Other trading activities	3	(426)	252
Investments	4	1,066	434
Total		81,529	87,581
Expenditure on:			
Charitable activities	5/6	(72,615)	(76,045)
Total		(72,615)	(76,045)
Net income		8,914	11,536
Reconciliation of funds			
Total funds brought forward		90,383	78,847
Total funds carried forward		99,297	90,383

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2023

	Notes	2023 £	2022 £
Fixed assets			
Tangible assets	13	29	39
		29	39
Current assets			
Debtors	14	19,380	26,498
Cash at bank and in hand		88,658	67,692
		108,038	94,190
Creditors: amounts falling due within one year	15	(8,770)	(3,846)
Net current assets		99,268	90,344
Total assets less current liabilities		99,297	90,383
Net assets		99,297	90,383
The funds of the charity			
Unrestricted income funds	16	99,297	90,383
Total funds		99,297	90,383

For the year ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,
- The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:



Corinna Freeman
Trustee

22 August 2024

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2023

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

During 2023 BSHI was able to continue with its objectives with another successful year of member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2023

2. Income from charitable activities

	2023	2022
	£	£
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	17,850	18,800
Subscriptions	26,080	26,860
Conference	2,800	17,975
Qualifications	24,045	14,680
	70,775	78,315
<i>Other member activities</i>		
Other member activities	-	100
Income from charitable activities	10,114	8,480
	10,114	8,580
	80,889	86,895

3. Income earned from other activities

	2023	2022
	£	£
Unrestricted funds		
Fund raising events	(426)	252
	(426)	252

4. Investment income

	2023	2022
	£	£
Unrestricted funds		
Bank interest receivable	1,066	434
	1,066	434

5. Costs of charitable activities by fund type

	2023	2022
	£	£
Unrestricted funds		
Charitable activities	25,627	26,474
Support costs	46,988	49,571
	72,615	76,045

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2023

6. Costs of charitable activities by activity type

	Activities undertaken directly £	Support costs £	2023 £	2022 £
Support costs				
Charitable activities	25,627	46,988	72,615	76,045

7. Analysis of support costs

	2023 £	2022 £
Charitable activities		
Finance	1,288	1,794
Computer costs	560	2,053
Depreciation & amortisation	10	13
EBS Admin charges	31,697	27,764
International Journal of Immunogenetics	6,500	13,000
Print, post & stationery	53	62
Subscriptions	580	593
Telephone	67	82
Governance costs	6,233	4,210
	46,988	49,571

8. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2023 £	2022 £
Depreciation of owned fixed assets	10	13
Accountancy fees	1,440	1,200

9. Particulars of employees

	2023	2022
Employees	0	0
	0	0

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2023

11. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

12. Intangible fixed assets

	Intangible asset 1
Cost or valuation	£
At 01 January 2023	6,668
At 31 December 2023	6,668
Amortisation	
At 01 January 2023	6,668
At 31 December 2023	6,668
Net book values	
At 31 December 2023	-
At 31 December 2022	-

13. Tangible fixed assets

	Plant and machinery
Cost or valuation	£
At 01 January 2023	380
At 31 December 2023	380
Depreciation	
At 01 January 2023	341
Charge for year	10
At 31 December 2023	351
Net book values	
At 31 December 2023	29
At 31 December 2022	39

14. Debtors

	2023	2022
	£	£
Amounts due within one year:		
Trade debtors	19,380	26,498
	19,380	26,498

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2023

15. Creditors: amounts falling due within one year

	2023	2022
	£	£
Trade creditors	7,330	2,646
Accruals and deferred income	1,440	1,200
	<u>8,770</u>	<u>3,846</u>

16. Movement in funds

Unrestricted Funds

	Balance at 01/01/2023	Incoming resources	Outgoing resources	Balance at 31/12/2023
	£	£	£	£
<i>General</i>				
General	90,383	81,529	(72,615)	99,297
	<u>90,383</u>	<u>81,529</u>	<u>(72,615)</u>	<u>99,297</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2022	Incoming resources	Outgoing resources	Balance at 31/12/2022
	£	£	£	£
<i>General</i>				
General	78,847	87,581	(76,045)	90,383
	<u>78,847</u>	<u>87,581</u>	<u>(76,045)</u>	<u>90,383</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

17. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	29	99,268	99,297
	<u>-</u>	<u>29</u>	<u>99,268</u>	<u>99,297</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2023

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
<i>General</i>				
General	-	39	90,344	90,383
	-	39	90,344	90,383

18. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2023

	2023 £	2022 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising (Charitable activities)	17,850	18,800
Subscriptions (Charitable activities)	26,080	26,860
Conference (Charitable activities)	2,800	17,975
Qualifications (Charitable activities)	24,045	14,680
Other member activities (Other member activities)	-	100
Income from charitable activities (Other member activities)	10,114	8,480
	80,889	86,895
Other trading activities		
Fund raising events	(426)	252
	(426)	252
Investments		
Bank interest receivable	1,066	434
	1,066	434
Total incoming resources	81,529	87,581
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity (Charitable activities)	(25,627)	(26,474)
	(25,627)	(26,474)
SUPPORT COSTS		
Finance		
Finance (Charitable activities)	(1,288)	(1,794)
	(1,288)	(1,794)
Computer costs		
Computer costs (Charitable activities)	(560)	(2,053)
	(560)	(2,053)
Depreciation & amortisation		
Depreciation & amortisation (Charitable activities)	(10)	(13)
	(10)	(13)
EBS Admin charges		
EBS Admin charges (Charitable activities)	(31,697)	(27,764)
	(31,697)	(27,764)
International Journal of Immunogenetics		
International Journal of Immunogenetics (Charitable activities)	(6,500)	(13,000)
	(6,500)	(13,000)
Print, post & stationery		
Print, post & stationery (Charitable activities)	(53)	(62)

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2023

	(53)	(62)
Subscriptions		
Subscriptions (Charitable activities)	(580)	(593)
	(580)	(593)
Telephone		
Telephone (Charitable activities)	(67)	(82)
	(67)	(82)
Governance costs		
Governance costs (Charitable activities)	(6,233)	(4,210)
	(6,233)	(4,210)
Total resources expended	(72,615)	(76,045)
Net Income	8,914	11,536

Accounts

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2022

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2022

Report of the Trustees	1 to 4
Independent Examiner's Report to the Trustees	5
Statement of Financial Activities	6
Statement of Financial Position	7
Notes to the Financial Statements	8 to 13
Detailed Statement of Financial Activities	14 to 15

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2022

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2022. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference was held in person in 2022. The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of Histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present posters, short talks and case studies.

Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduating diplomats received their awards at the Annual Conference.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2022

ACHIEVEMENTS AND PERFORMANCE CONTINUED

Special Interest Groups

The three special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g., European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Cisco Webex and Zoom Meeting to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have increased to £90,383 showing recovery from COVID-19 restrictions being lifted. The reserves leave the charity in a strong position to continue to pursue its objectives for the foreseeable future.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2022

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	11237606078396
Company registration number	
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Sarah Peacock
Richard Battle
Mian Chen
Marie Hampson
(Resigned: 01 February 2022)
Helena Lee
Carla Rosser
Deborah Sage
Natalia Diaz Burlinson
(Resigned: 01 February 2022)
Franco Tavarozzi
Rachel Smith
Jessie Martin
(Appointed: 01 February 2022)
Emily Ryan
(Appointed: 01 February 2022)

Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2022

Approved by the Board of Trustees and signed on its behalf by

Corinna.Freeman..... 31st August 2023

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2022

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2022.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

Marie Hartwell
VESEY Accounting Services Ltd
Suite 1, Trinity House
33a Market Street
Lichfield, Staffs
WS13 6LA
31st August 2023

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2022

	Notes	Unrestricted funds £	2021 £
Income and endowments from:			
Charitable activities	2	86,895	46,674
Other trading activities	3	252	-
Investments	4	434	390
Total		87,581	47,064
Expenditure on:			
Charitable activities	5/6	(76,045)	(74,152)
Total		(76,045)	(74,152)
Net income/expenditure		11,536	(27,088)
Reconciliation of funds			
Total funds brought forward		78,847	105,935
Total funds carried forward		90,383	78,847

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2022

	Notes	2022 £	2021 £
Fixed assets			
Tangible assets	13	39	51
		39	51
Current assets			
Debtors	14	26,498	10,532
Cash at bank and in hand		67,692	72,954
		94,190	83,486
Creditors: amounts falling due within one year	15	(3,846)	(4,690)
Net current assets		90,344	78,796
Total assets less current liabilities		90,383	78,847
Net assets		90,383	78,847
The funds of the charity			
Unrestricted income funds	16	90,383	78,847
Total funds		90,383	78,847

For the year ended 31 December 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:

.....
Corinna Freeman 31st August 2023
Trustee

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2022

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

During 2022 BSHI was able to move towards recovery from the impact of COVID-19. The increase in member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2022

2. Income from charitable activities

	2022	2021
	£	£
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	18,800	11,350
Subscriptions	26,860	20,410
Conference	17,975	(571)
Qualifications	14,680	14,285
	78,315	45,474
<i>Other member activities</i>		
Sponsorship Income	8,480	1,200
Income from charitable activities	100	-
	8,580	1,200
	86,895	46,674

3. Income earned from other activities

	2022	2021
	£	£
Unrestricted funds		
Fund raising events	252	-
	252	-

4. Investment income

	2022	2021
	£	£
Unrestricted funds		
Bank interest receivable	434	390
	434	390

5. Costs of charitable activities by fund type

	2022	2021
	£	£
Unrestricted funds		
Charitable activities	26,474	29,965
Support costs	49,571	44,187
	76,045	74,152

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2022

6. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2022	2021
	£	£	£	£
Support costs				
Charitable activities	26,474	49,571	76,045	74,152

7. Analysis of support costs

	2022	2021
	£	£
Charitable activities		
Finance	1,794	808
Computer costs	2,053	2,121
Depreciation & amortisation	13	17
EBS Admin charges	27,764	22,406
International Journal of Immunogenetics	13,000	12,296
Print, post & stationery	62	17
Subscriptions	593	564
Telephone	82	92
Governance costs	4,210	5,866
	49,571	44,187

8. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2022	2021
	£	£
Depreciation of owned fixed assets	13	17
Accountancy fees	1,200	1,200

9. Particulars of employees

	2022	2021
	£	£
Employees	0	0
	0	0

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2022

11. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

12. Intangible fixed assets

	Intangible asset 1
	£
Cost or valuation	
At 01 January 2022	6,668
At 31 December 2022	6,668
Amortisation	
At 01 January 2022	6,668
At 31 December 2022	6,668
Net book values	
At 31 December 2022	-
At 31 December 2021	-

13. Tangible fixed assets

	Plant and machinery
	£
Cost or valuation	
At 01 January 2022	380
At 31 December 2022	380
Depreciation	
At 01 January 2022	329
Charge for year	12
At 31 December 2022	341
Net book values	
At 31 December 2022	39
At 31 December 2021	51

14. Debtors

	2022	2021
	£	£
Amounts due within one year:		
Trade debtors	26,498	10,532
	26,498	10,532

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2022

15. Creditors: amounts falling due within one year

	2022	2021
	£	£
Trade creditors	2,646	3,490
Accruals and deferred income	1,200	1,200
	<u>3,846</u>	<u>4,690</u>

16. Movement in funds

Unrestricted Funds

	Balance at 01/01/2022	Incoming resources	Outgoing resources	Balance at 31/12/2022
	£	£	£	£
General	78,847	87,581	(76,045)	90,383
	<u>78,847</u>	<u>87,581</u>	<u>(76,045)</u>	<u>90,383</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2021	Incoming resources	Outgoing resources	Balance at 31/12/2021
	£	£	£	£
General	105,935	47,064	(74,152)	78,847
	<u>105,935</u>	<u>47,064</u>	<u>(74,152)</u>	<u>78,847</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

17. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	39	90,344	90,383
	<u>-</u>	<u>39</u>	<u>90,344</u>	<u>90,383</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2022

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	51	78,796	78,847
	-	51	78,796	78,847

18. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2022

	2022 £	2021 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising	18,800	11,350
Subscriptions	26,860	20,410
Conference	17,975	(571)
Qualifications	14,680	14,285
Sponsorship Income	8,480	1,200
Income from charitable activities	100	-
	86,895	46,674
Other trading activities		
Fund raising events	252	-
	252	-
Investments		
Bank interest receivable	434	390
	434	390
Total incoming resources	87,581	47,064
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity	(26,474)	(29,965)
	(26,474)	(29,965)
SUPPORT COSTS		
Finance		
Finance	(1,794)	(808)
	(1,794)	(808)
Computer costs		
Computer costs	(2,053)	(2,121)
	(2,053)	(2,121)
Depreciation & amortisation		
Depreciation & amortisation	(13)	(17)
	(13)	(17)
EBS Admin charges		
EBS Admin charges	(27,764)	(22,406)
	(27,764)	(22,406)
International Journal of Immunogenetics		
International Journal of Immunogenetics	(13,000)	(12,296)
	(13,000)	(12,296)
Print, post & stationery		
Print, post & stationery	(62)	(17)
	(62)	(17)

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2022

Subscriptions		
Subscriptions	(593)	(564)
	(593)	(564)
Telephone		
Telephone	(82)	(92)
	(82)	(92)
Governance costs		
Governance costs	(4,210)	(5,866)
	(4,210)	(5,866)
Total resources expended	(76,045)	(74,152)
Net Income	11,536	(27,088)

Accounts

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2021

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2021

Report of the Trustees	1 to 3
Independent Examiner's Report to the Trustees	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 12
Detailed Statement of Financial Activities	13 to 14

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2021

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2021. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference for 2020 was postponed due to the COVID-19 pandemic. It was held jointly with the European Federation of immunogenetics (EFI) in April 2021 as a virtual event. The meeting provided an educational programme of lectures and seminars. Plenary lectures were provided by world experts in the field of Histocompatibility and Immunogenetics. Sessions were run allowing BSHI Members to present short papers and posters of their current research to a worldwide audience of experts.

Two awards sessions were held. The first for best abstract submitted and a session dedicated to presentations from young scientists within the society.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

Special Interest Groups

The three special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2021

ACHIEVEMENTS AND PERFORMANCE Continued

Bursaries and Grants

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Zoom Meeting to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact. The majority training and education activities for the BSHI diploma has now been moved online.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have decreased to £78,847 due to a slow recovery from COVID-19 and restrictions. However, the reserves are still leaving the charity in a strong position to continue to pursue its objectives for the foreseeable future.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2021

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Sarah Peacock
Richard Battle
Mian Chen
Marie Hampson
Helena Lee
Carla Rosser
Deborah Sage
Natalia Diaz Burlinson
Franco Tavarozzi
Rachel Smith

Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

Mian.Chen.....

29th June 2022

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2021

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

29th June 2022

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2021

	Notes	Unrestricted funds £	2020 £
Income and endowments from:			
Charitable activities	2	46,674	35,271
Investments	3	390	656
Total		47,064	35,927
Expenditure on:			
Charitable activities	4/5	(74,152)	(71,643)
Total		(74,152)	(71,643)
Net expenditure		(27,088)	(35,716)
Reconciliation of funds			
Total funds brought forward		105,935	141,652
Total funds carried forward		78,847	105,936

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2021

	Notes	2021 £	2020 £
Fixed assets			
Tangible assets	12	51	68
		51	68
Current assets			
Debtors	13	10,532	15,085
Cash at bank and in hand		72,954	94,132
		83,486	109,217
Creditors: amounts falling due within one year	14	(4,690)	(3,349)
Net current assets		78,796	105,868
Total assets less current liabilities		78,847	105,936
Net assets		78,847	105,936
The funds of the charity			
Unrestricted income funds	15	78,847	105,936
Total funds		78,847	105,936

For the year ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:

.....
Mian Chen 29th June 2022

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2021

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

In common with many other organisations, the outbreak of COVID-19 and the measures being taken to control its spread, have had a detrimental impact on the financial year ending 31st December 2021. Individual member subscriptions have increased on last year but still down on years prior to COVID-19, mainly as a result of social distancing measures and no Workshop Training was able to take place. At the date of reporting the accounts, it is felt the impact of the COVID-19 pandemic is now minimal and hopeful that future years will revert to pre Covid-19 times and therefore, the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2021

2. Income from charitable activities

	2021 £	2020 £
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	11,350	7,020
Subscriptions	20,410	11,815
Conference	(571)	(2,419)
Qualifications	14,285	18,755
	45,474	35,171
<i>Other member activities</i>		
Other member activities	-	100
Sponsorship Income	1,200	-
	1,200	100
	46,674	35,271

3. Investment income

	2021 £	2020 £
Unrestricted funds		
Bank interest receivable	390	656
	390	656

4. Costs of charitable activities by fund type

	2021 £	2020 £
Unrestricted funds		
Charitable activities	29,965	33,492
Support costs	44,187	38,151
	74,152	71,643

5. Costs of charitable activities by activity type

	Activities undertaken directly £	Support costs £	2021 £	2020 £
Support costs				
Charitable activities	29,965	44,187	74,152	71,643

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2021

6. Analysis of support costs

	2021	2020
	£	£
Charitable activities		
Management	-	2,052
Finance	808	541
Computer costs	2,121	2,379
Depreciation & amortisation	17	2,246
EBS Admin charges	22,406	18,165
International Journal of Immunogenetics	12,296	5,414
Print, post & stationery	17	39
Subscriptions	564	1,120
Telephone	92	1,133
Governance costs	5,866	5,062
	44,187	38,151

7. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2021	2020
	£	£
Depreciation of owned fixed assets	17	23
Amortisation of intangible fixed assets	-	2,223
Accountancy fees	1,200	1,200

8. Particulars of employees

	2021	2020
Employees	0	0
	0	0

10. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2021

11. Intangible fixed assets

	Intangible asset 1
Cost or valuation	£
At 01 January 2021	6,668
At 31 December 2021	6,668
Amortisation	
At 01 January 2021	6,668
At 31 December 2021	6,668
Net book values	
At 31 December 2021	-
At 31 December 2020	-

12. Tangible fixed assets

	Plant and machinery
Cost or valuation	£
At 01 January 2021	380
At 31 December 2021	380
Depreciation	
At 01 January 2021	312
Charge for year	17
At 31 December 2021	329
Net book values	
At 31 December 2021	51
At 31 December 2020	68

13. Debtors

	2021	2020
	£	£
Amounts due within one year:		
Trade debtors	10,532	3,472
Prepayments and accrued income	-	11,613
	10,532	15,085

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2021

14. Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors and accruals	4,690	3,349
	<u>4,690</u>	<u>3,349</u>

15. Movement in funds

Unrestricted Funds

	Balance at 01/01/2021	Incoming resources	Outgoing resources	Balance at 31/12/2021
	£	£	£	£
General	105,935	47,064	(74,152)	78,847
	<u>105,935</u>	<u>47,064</u>	<u>(74,152)</u>	<u>78,847</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2020	Incoming resources	Outgoing resources	Balance at 31/12/2020
	£	£	£	£
General	141,652	35,927	(71,643)	105,936
	<u>141,652</u>	<u>35,927</u>	<u>(71,643)</u>	<u>105,936</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

16. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	51	78,796	78,847
	<u>-</u>	<u>51</u>	<u>78,796</u>	<u>78,847</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2021

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	68	105,868	105,936
	-	68	105,868	105,936

17. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2021

	2021 £	2020 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising	11,350	7,020
Subscriptions	20,410	11,815
Conference	(571)	(2,419)
Qualifications	14,285	18,755
Other member activities	-	100
Sponsorship Income	1,200	-
	46,674	35,271
Investments		
Bank interest receivable	390	656
	390	656
Total incoming resources	47,064	35,927
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity	(29,965)	(33,492)
	(29,965)	(33,492)
SUPPORT COSTS		
Management		
Management	-	(2,052)
	-	(2,052)
Finance		
Finance	(808)	(541)
	(808)	(541)
Computer costs		
Computer costs	(2,121)	(2,379)
	(2,121)	(2,379)
Depreciation & amortisation		
Depreciation & amortisation	(17)	(2,246)
	(17)	(2,246)
EBS Admin charges		
EBS Admin charges	(22,406)	(18,165)
	(22,406)	(18,165)
International Journal of Immunogenetics		
International Journal of Immunogenetics	(12,296)	(5,414)
	(12,296)	(5,414)
Print, post & stationery		
Print, post & stationery	(17)	(39)
	(17)	(39)

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2021

Subscriptions		
Subscriptions	(564)	(1,120)
	(564)	(1,120)
Telephone		
Telephone	(92)	(1,133)
	(92)	(1,133)
Governance costs		
Governance costs	(5,866)	(5,062)
	(5,866)	(5,062)
Total resources expended	(74,152)	(71,643)
Net Expenditure	(27,088)	(35,716)

Accounts

Charity number: 1123760
Company number: 6078396
(England and Wales)

British Society for Histocompatibility and Immunogenetics
Report of the Trustees and Unaudited Financial Statements
For the year ended 31 December 2020

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2020

Report of the Trustees	1 to 3
Independent Examiner's Report to the Trustees	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 12
Detailed Statement of Financial Activities	13 to 14

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2020

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2020. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

BSHI Annual Conference for 2020 was postponed due to the COVID-19 pandemic. It was held jointly with the European Federation of Immunogenetics (EFI) in April 2021 as a virtual event. The meeting provided an educational programme of lectures and seminars. Plenary lectures were provided by world experts in the field of Histocompatibility and Immunogenetics. Sessions were run allowing BSHI Members to present short papers and posters of their current research to a worldwide audience of experts.

Two awards sessions were held. The first for best abstract submitted and a session dedicated to presentations from young scientists within the society.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduating diplomats received their awards at the Annual Conference.

BSHI ran a higher training meeting for members considering taking the FRC Path examinations.

BSHI also administers a CPD scheme for the membership.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE CONTINUED

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings.

The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents.

BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups.

Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Virtual Conference Facility

BSHI provides virtual conference infrastructure via Cisco Webex and Zoom meeting to the memberships, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Online CPD Scheme

BSHI provides and manages online Continuing Professional Development (CPD) schemes for its members via CPDMe.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have decreased to £105,936 due to COVID-19 restrictions. However, the reserves are still leaving the charity in a strong position to continue to pursue its objectives for the foreseeable future.

Going concern

The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future.

British Society for Histocompatibility and Immunogenetics
Report of the Trustees Continued
For the year ended 31 December 2020

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ

Trustees

The trustees and officer serving during the year and since the year end were as follows:

Sarah Peacock
Richard Battle
Mian Chen
Marie Hampson
Helena Lee
Carla Rosser
Andrea Harmer Resigned Dec 2020
Paul Dunn Resigned Dec 2020
Deborah Sage
Natalia Diaz Burlinson
Franco Tavarozzi
Rachel Smith Appointed Dec 2020

Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

Mian Chen.....  14 May 2021

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2020

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2020.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.



Marie Hartwell
VESEY Accounting Services Ltd
34 High Street
Sutton Coldfield
West Midlands
B72 1UP
14 May 2021

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2020

	Notes	Unrestricted funds £	2019 £
Income and endowments from:			
Charitable activities	2	35,271	69,788
Investments	3	656	869
Total		35,927	70,657
Expenditure on:			
Charitable activities	4/5	(71,643)	(68,828)
Total		(71,643)	(68,828)
Net Income/expenditure		(35,716)	1,829
Reconciliation of funds			
Total funds brought forward		141,652	139,823
Total funds carried forward		105,936	141,652

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2020

	Notes	2020 £	2019 £
Fixed assets			
Intangible assets	11	-	2,223
Tangible assets	12	68	91
		<u>68</u>	<u>2,314</u>
Current assets			
Debtors	13	15,085	27,742
Cash at bank and in hand		94,132	114,716
		<u>109,217</u>	<u>142,458</u>
Creditors: amounts falling due within one year	14	(3,349)	(3,120)
Net current assets		<u>105,868</u>	<u>139,338</u>
Total assets less current liabilities		<u>105,936</u>	<u>141,652</u>
Net assets		<u>105,936</u>	<u>141,652</u>
The funds of the charity			
Unrestricted income funds	15	105,936	141,652
Total funds		<u>105,936</u>	<u>141,652</u>

For the year ended 31 December 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:


Mian Chen
Trustee

14 May 2021

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements
For the year ended 31 December 2020

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

Since 31 December 2019, in common with many other organisations, the outbreak of COVID-19 and the measures being taken to control its spread, have had a detrimental impact on the financial year ending 31st December 2020. Specifically, Individual member subscriptions are just over a 3rd of the previous year and due to lockdown and social distancing measures no Workshop Training was able to take place. At the date of reporting the accounts, the duration and impact of the COVID-19 pandemic, as well as the effectiveness of government lockdown measures and the roll out of the vaccination programmes remains unclear at this time. It is not possible to reliably estimate the duration and severity of these consequences, as well as their impact on the financial position and results of the organisation for future periods. However, the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future.

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and machinery	25% Reducing balance
Computer equipment	25% Reducing balance
Motor vehicles	25% Reducing balance
Fixtures and fittings	25% Reducing balance

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

2. Income from charitable activities

	2020 £	2019 £
Unrestricted funds		
<i>Charitable activities</i>		
Advertising	7,020	15,825
Subscriptions	11,815	32,620
Conference	(2,419)	1,205
Qualifications	18,755	19,218
	<u>35,171</u>	<u>68,868</u>
<i>Other member activities</i>		
Other member activities	100	920
	<u>35,271</u>	<u>69,788</u>

3. Investment income

	2020 £	2019 £
Unrestricted funds		
Bank interest receivable	656	869
	<u>656</u>	<u>869</u>

4. Costs of charitable activities by fund type

	2020 £	2019 £
Unrestricted funds		
Charitable activities	33,492	35,976
Support costs	38,151	32,852
	<u>71,643</u>	<u>68,828</u>

5. Costs of charitable activities by activity type

	Activities undertaken directly £	Support costs £	2020 £	2019 £
Support costs				
Charitable activities	33,492	38,151	71,643	68,828

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

6. Analysis of support costs

	2020	2019
	£	£
Charitable activities		
Management	2,052	9,213
Finance	541	1,466
Computer costs	2,379	3,613
Depreciation & amortisation	2,246	2,253
EBS Admin charges	18,165	11,433
International Journal of Immunogenetics	5,414	-
Print, post & stationery	39	116
Subscriptions	1,120	794
Telephone	1,133	1,311
Governance costs	5,062	2,653
	<u>38,151</u>	<u>32,852</u>

7. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2020	2019
	£	£
Depreciation of owned fixed assets	23	30
Amortisation of intangible fixed assets	2,223	2,223
Accountancy fees	1,200	1,200

8. Staff costs

No staff costs or emoluments were paid in the year.

	2020	2019
Employees	0	0
	<u>0</u>	<u>0</u>

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

10. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

11. Intangible fixed assets

	Intangible asset 1
Cost or valuation	£
At 01 January 2020	6,668
At 31 December 2020	<u>6,668</u>
Amortisation	
At 01 January 2020	4,445
Charge for year	2,223
At 31 December 2020	<u>6,668</u>
Net book values	
At 31 December 2020	<u>-</u>
At 31 December 2019	<u>2,223</u>

12. Tangible fixed assets

	Plant and machinery
Cost or valuation	£
At 01 January 2020	380
At 31 December 2020	<u>380</u>
Depreciation	
At 01 January 2020	289
Charge for year	23
At 31 December 2020	<u>312</u>
Net book values	
At 31 December 2020	<u>68</u>
At 31 December 2019	<u>91</u>

Tangible fixed assets

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

13. Debtors

	2020 £	2019 £
Amounts due within one year:		
Trade debtors	3,472	10,735
Prepayments and accrued income	11,613	17,007
	<u>15,085</u>	<u>27,742</u>

14. Creditors: amounts falling due within one year

	2020 £	2019 £
Trade creditors	3,349	3,120
	<u>3,349</u>	<u>3,120</u>

15. Movement in funds

Unrestricted Funds

	Balance at 01/01/2020 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2020 £
General	141,652	35,927	(71,643)	105,936
	<u>141,652</u>	<u>35,927</u>	<u>(71,643)</u>	<u>105,936</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2019 £	Incoming resources £	Outgoing resources £	Balance at 31/12/2019 £
General	139,823	70,657	(68,828)	141,652
	<u>139,823</u>	<u>70,657</u>	<u>(68,828)</u>	<u>141,652</u>

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

British Society for Histocompatibility and Immunogenetics
Notes to the Financial Statements Continued
For the year ended 31 December 2020

16. Analysis of net assets between funds

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	-	68	105,868	105,936
	-	68	105,868	105,936

Previous year

	Intangible fixed assets	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£	£
Unrestricted funds				
General	2,223	91	139,338	141,652
	2,223	91	139,338	141,652

17. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2020

	2020 £	2019 £
INCOME AND ENDOWMENT		
Charitable activities		
Advertising	7,020	15,825
Subscriptions	11,815	32,620
Conference	(2,419)	1,205
Qualifications	18,755	19,218
Other member activities	100	920
	35,271	69,788
Investments		
Bank interest receivable	656	869
	656	869
Total incoming resources	35,927	70,657
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity	(33,492)	(35,976)
	(33,492)	(35,976)
SUPPORT COSTS		
Management		
Management	(2,052)	(9,213)
	(2,052)	(9,213)
Finance		
Finance	(541)	(1,466)
	(541)	(1,466)
Computer costs		
Computer costs	(2,379)	(3,613)
	(2,379)	(3,613)
Depreciation & amortisation		
Depreciation & amortisation	(2,246)	(2,253)
	(2,246)	(2,253)
EBS Admin charges		
EBS Admin charges	(18,165)	(11,433)
	(18,165)	(11,433)
International Journal of Immunogenetics		
International Journal of Immunogenetics	(5,414)	-
	(5,414)	-
Print, post & stationery		
Print, post & stationery	(39)	(116)
	(39)	(116)
Subscriptions		

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities Continued
For the year ended 31 December 2020

Subscriptions	(1,120)	(794)
	(1,120)	(794)
Telephone		
Telephone	(1,133)	(1,311)
	(1,133)	(1,311)
Governance costs		
Governance costs	(5,062)	(2,653)
	(5,062)	(2,653)
Total resources expended	(71,643)	(68,828)
Net Expenditure	(35,716)	1,829